A New Hope for FSGS: Can Sparsentan Offer Better Results?
"DUET Study Reveals Promising Results for Sparsentan in Treating Primary FSGS, Offering a Potential Breakthrough for Patients."
Focal Segmental Glomerulosclerosis (FSGS) is a challenging kidney disease characterized by scarring in the kidney's filtering units. This scarring leads to proteinuria, where protein leaks into the urine, and can eventually lead to kidney failure. Primary FSGS, in particular, has no identifiable cause, making it difficult to treat effectively. Current treatments often involve managing symptoms and slowing disease progression.
Traditional treatments for primary FSGS include corticosteroids and other immune-modulating agents, often combined with renin-angiotensin system inhibitors (RASIs). However, these treatments can have significant side effects, leaving many patients with an unmet need for more effective and well-tolerated options. This is why researchers are constantly seeking new therapies to combat FSGS and protect kidney function.
The DUET study aimed to evaluate the efficacy and safety of sparsentan, a dual endothelin type A (ETA) and angiotensin II type 1 (AT1) receptor antagonist, compared to irbesartan, an angiotensin II type 1 receptor antagonist, in patients with primary FSGS. Sparsentan's dual-action approach targets two pathways involved in kidney damage, potentially offering a more comprehensive treatment strategy.
FSGS Treatment and Sparsentan’s Dual Target
Focal segmental glomerulosclerosis (FSGS) is a kidney lesion with varied causes and substantial unmet need for safe, effective treatments. Sparsentan is being studied because it targets endothelin-1 and angiotensin II pathways that contribute to kidney-function loss. In the 8-week, randomized, double-blind DUET study, sparsentan reduced urinary protein more than irbesartan, a blood-pressure medicine commonly used for FSGS. A later review describes the challenge of applying the FDA’s proteinuria-based indication to different FSGS phenotypes in clinical practice.
A First Disease-Specific FDA Milestone
On April 13, 2026, the FDA approved sparsentan (Filspari) for adults and children aged 8 years and older with FSGS without nephrotic syndrome, according to Medaptly. A September 2026 Kidney News commentary describes the approval as the first targeted therapy for FSGS to move beyond conventional renin-angiotensin-aldosterone system inhibition. The milestone marks a new treatment option, while the commentary also notes that it brings unresolved questions alongside promise.
Sparsentan's Dual Action: A More Effective Approach to Reducing Proteinuria?
The DUET study was a Phase 2, randomized, double-blind, active-controlled trial. This means patients were randomly assigned to receive either sparsentan or irbesartan, and neither the patients nor the researchers knew which treatment each patient was receiving until the study was completed. This design helps to minimize bias and ensure the results are reliable.
- Greater Proteinuria Reduction: Patients treated with sparsentan experienced a significantly greater reduction in proteinuria compared to those treated with irbesartan.
- FSGS Partial Remission: A higher proportion of sparsentan-treated patients achieved FSGS partial remission, meaning their proteinuria levels decreased significantly.
- Blood Pressure Control: Sparsentan effectively reduced blood pressure, while irbesartan did not demonstrate the same effect.
- Stable Kidney Function: Both treatments maintained stable kidney function (eGFR), indicating they did not negatively impact kidney health.
Evidence Base Across Four Studies
A 2024 systematic review and meta-analysis included four studies in its quantitative and qualitative synthesis: Trachtman 2018, Rheault 2023, Heerspink 2023, and Rovin 2023. A 2022 review notes that sparsentan was evaluated in DUET, a phase 2, double-blinded, active-control trial in FSGS. A 2026 review describes the study population as 109 patients aged 8–75 years with presumed primary, genetic, and possibly secondary FSGS lesions, eGFR above 30 mL/min/1.73 m², and urine protein-to-creatinine ratio of at least 1.0 g/g.
Limits of DUET Evidence
The DUET study enrolled relatively few patients in each dose cohort, limiting its ability to detect significant differences in antiproteinuric effect between individual dose groups. Its FSGS population was heterogeneous, including immunologically mediated and genetic disease and varying degrees of interstitial fibrosis. The long-term post hoc analysis also has potential selection bias: patients who chose to remain in the study may have been those who responded well to sparsentan.
Proteinuria Reduction and Kidney-Function Outcomes
The phase 2 DUET trial found that sparsentan reduced proteinuria compared with irbesartan over eight weeks. In the phase 3 DUPLEX trial, sparsentan was compared with the maximum labeled dose of irbesartan, and the supplied pediatric report describes rapid and sustained proteinuria reductions with sparsentan. However, a March 2024 letter reports no significant difference in estimated glomerular filtration rate slope over 108 weeks in the comparison it discusses. These findings distinguish proteinuria reduction from evidence of a difference in eGFR slope.
Looking Ahead: Sparsentan's Potential and Future Research
The DUET study provides compelling evidence that sparsentan may offer a more effective treatment option for patients with primary FSGS. Its dual-action mechanism, targeting both endothelin and angiotensin II receptors, appears to be more effective at reducing proteinuria than traditional RASI therapy alone.
Why Dual Pathway Targeting Matters
Sparsentan acts on both endothelin and angiotensin pathways. A 2024 Kidney Medicine article presents this dual mechanism as a reason the drug could reduce proteinuria more effectively than single-agent RAAS inhibitors or endothelin A receptor antagonists alone. The source frames this as potential enhanced efficacy, rather than establishing that advantage as a settled outcome.
While these results are promising, it's important to remember that this was a Phase 2 study. Further research is needed to confirm these findings in larger, longer-term trials. The ongoing open-label treatment period of the DUET study and the Phase 3 DUPLEX study will provide valuable insights into the long-term effects of sparsentan on kidney function and overall patient outcomes.
If future studies confirm sparsentan's efficacy and safety, it could represent a significant advance in the management of FSGS, offering patients a new hope for preserving kidney function and improving their quality of life.